Lipid‐modifying statins, fibrates reduce mortality in schizophrenia patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Source:
    Brown University Psychopharmacology Update. Sep2024, Vol. 35 Issue 9, p1-6. 6p.
  • Additional Information
    • Subject Terms:
      DRUG therapy for schizophrenia; LIPID metabolism; CLOFIBRIC acid; DEATH; SCHIZOPHRENIA; STATINS (Cardiovascular agents)
    • Abstract:
      A nationwide cohort study conducted in Taiwan has found that lipid‐modifying agents, particularly statins and fibrates, reduce mortality risk in patients with schizophrenia. The reduced risk was apparent for both all‐cause and natural‐cause mortality, the investigators reported. Study results were published online May 16, 2024, in The British Journal of Psychiatry. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Brown University Psychopharmacology Update is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)